Ebola virus is a filamentous, membrane-wrapped particle that hijacks its host’s own cellular machinery at nearly every step of infection, from the moment it latches onto a cell to the way it blinds the immune system while copying itself. Its genome is a single strand of negative-sense RNA encoding just seven genes, yet the proteins those genes produce orchestrate a remarkably efficient infection cycle. Understanding how the virus is built, how it breaks into cells, how it replicates, and how it manipulates the host response reveals both why Ebola is so dangerous and where its vulnerabilities lie.
The Filamentous Virion
Ebola particles look nothing like the neat spheres most people picture when they think of a virus. They are long, thread-like filaments that vary in length but maintain a consistent width of roughly 65 nanometers.1PubMed Central. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP Some particles stretch beyond 20 micrometers, and the virus can even package multiple copies of its genome end to end, creating extended structures with a modular layout.2PLoS ONE. The Organisation of Ebola Virus Reveals a Capacity for Extensive, Modular Polyploidy At the core sits the nucleocapsid, a helical tube formed by the nucleoprotein (NP) wrapped around the RNA genome, decorated with protruding arms made of VP24 and VP35.3PubMed Central. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography This nucleocapsid has been measured at about 41 nanometers across, with a hollow inner channel roughly 16 nanometers wide.2PLoS ONE. The Organisation of Ebola Virus Reveals a Capacity for Extensive, Modular Polyploidy
Surrounding the nucleocapsid is a layer of the matrix protein VP40, which forms a regular lattice just beneath the viral envelope. VP40 is the driving force behind the filamentous shape: when expressed alone in cells, it induces budding of elongated particles from the plasma membrane.1PubMed Central. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP The outermost layer is a lipid membrane stolen from the host cell, studded with trimeric spikes of the glycoprotein GP, the only viral protein exposed on the surface and the molecule responsible for attaching to and entering new cells.
The Glycoprotein and Its Processing
GP is synthesized as a precursor that gets cleaved into two subunits, GP1 and GP2, which remain linked by a disulfide bond. The enzyme furin, a host protease that normally processes cellular proteins, handles this cleavage. Experiments in cells lacking furin showed that GP processing did not occur, while restoring furin rescued the cleavage.4PubMed Central. Processing of the Ebola virus glycoprotein by the proprotein convertase furin That said, furin may not be the only protease capable of performing this cut: mutational work has shown that although the cleavage site resembles a furin recognition motif, furin is not strictly required for GP processing to happen.5PubMed Central. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function The assembled GP trimer sits on the virion surface shielded by a heavy coat of sugar molecules, which helps mask it from immune recognition.
Interestingly, GP is not the only product of the GP gene. The primary transcript actually encodes a shorter, soluble form called sGP, which is secreted in large quantities during infection. Because sGP shares much of its sequence with the surface-displayed GP, it may act as a decoy, soaking up antibodies that would otherwise target the virus.6PubMed Central. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development Producing the full-length GP requires the polymerase to “stutter” at a specific editing site in the gene, inserting an extra nucleotide that shifts the reading frame. This means the virus deliberately limits how much surface GP it makes, favoring secretion of the decoy instead.
How the Virus Gets Inside a Cell
Ebola does not simply fuse at the cell surface the way some viruses do. Instead, it tricks the cell into swallowing it whole through a process called macropinocytosis, a form of bulk fluid uptake in which the cell membrane ruffles outward and then folds back to engulf large volumes of extracellular material. Fluorescently labeled Ebola particles co-localize with markers specific to macropinosomes, and their uptake depends on cellular enzymes involved in macropinocytosis, including specific GTPases and kinases.7PLOS Pathogens. Ebolavirus Is Internalized into Host Cells via Macropinocytosis in a Viral Glycoprotein-Dependent Manner This process is GP-dependent: the glycoprotein actively stimulates the membrane ruffling that triggers uptake.
A second, minor entry route also exists. A fraction of virus-like particles has been observed co-localizing with clathrin, the coat protein used in the more conventional endocytic pathway, and knocking down clathrin reduced viral uptake to some degree. However, caveolae-mediated entry does not appear to play a role.8PubMed Central. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis So the picture is one of a dominant macropinocytic route supplemented by a clathrin-dependent backup.
Inside the Endosome
Once inside the cell, the virus particle sits in an endosomal compartment that progressively acidifies. This acidic environment activates host proteases called cathepsins, which strip away most of the GP1 subunit, including its bulky glycan cap. Cathepsin cleavage proceeds through intermediate fragments, ultimately generating a small core of about 19 kilodaltons.9PubMed Central. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change Cathepsin L in particular has been shown to produce a stable intermediate that binds more tightly to target cells and is more infectious than the unprocessed form.10PubMed Central. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity
This trimming step is not merely a byproduct of the harsh endosomal environment. It exposes a hidden binding site on GP that allows the virus to interact with its intracellular receptor, a cholesterol-transporting protein called Niemann-Pick C1 (NPC1) embedded in the endosomal membrane. NPC1 is essential for Ebola infection: cells lacking functional NPC1 are resistant to the virus, and small-molecule inhibitors that block GP from binding NPC1 prevent infection entirely.11PubMed Central. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection Crystal structures show that domain C of NPC1 uses two protruding loops to reach into a hydrophobic pocket on the trimmed GP, an interaction that only becomes possible after cathepsin processing.12Cell. Crystal Structure of the Ebola Virus Glycoprotein Bound to Its Intracellular Receptor NPC1
After NPC1 engagement, the virus still needs the endosome to become sufficiently acidic and for calcium levels to shift before the GP2 fusion subunit rearranges into its fusion-active conformation. Experiments tracking conformational changes in GP2 showed that lowering the pH causes a stepwise destabilization of the prefusion structure, pushing the GP2 N-terminus into new positions consistent with the beginning of membrane fusion.13PubMed Central. Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca 2+ , and receptor binding When conditions align, GP2 drives the viral and endosomal membranes together, releasing the nucleocapsid into the cell’s cytoplasm.
Replication and Transcription
Once the nucleocapsid reaches the cytoplasm, the viral polymerase complex takes over. This complex consists of the large L protein and its cofactor VP35, together forming the machine responsible for copying and transcribing the RNA genome.14PubMed Central. Structure of the Ebola virus polymerase complex The L protein carries all the catalytic activities needed for RNA synthesis, while VP35 acts as a bridge, linking L to the nucleocapsid template and helping to organize the complex structurally. Because this polymerase partnership is shared across filoviruses, it has attracted interest as a target for broadly acting antiviral drugs.
Transcription of the Ebola genome has an unusual requirement: a small protein called VP30, which acts as a transcription activator. VP30 is needed specifically for initiating transcription and for reinitiating it at each gene junction along the genome.15PubMed Central. Role of Ebola virus VP30 in transcription reinitiation This activity is regulated by phosphorylation: when VP30 is phosphorylated at a cluster of N-terminal serine residues, its ability to activate transcription is dampened; when those residues are unphosphorylated, VP30 supports transcription efficiently.16Journal of Biological Chemistry. Phosphorylation of VP30 Impairs Ebola Virus Transcription The virus appears to exploit this toggle: phosphorylated VP30 associates more readily with NP-containing inclusion bodies and is needed to transport the protein to sites of RNA synthesis, while dephosphorylated VP30 performs the actual transcription activation.17PubMed Central. Dynamic Phosphorylation of VP30 Is Essential for Ebola Virus Life Cycle This dynamic cycling between phosphorylated and dephosphorylated states is essential for a productive infection.
Nucleocapsid Assembly and Budding
As new copies of the viral genome accumulate, they must be packaged into nucleocapsids for export. NP polymerizes along the RNA, and VP24 and VP35 join the growing structure to condense it into the mature helical nucleocapsid.18PubMed Central. Intracellular Ebola virus nucleocapsid assembly revealed by in situ cryo-electron tomography Structural studies have resolved the repeating unit within the nucleocapsid and shown that VP24 molecules sit in two distinct orientations relative to NP, suggesting VP24 plays a regulatory role in shaping the helix.19Nature Communications. Structural basis for Ebola virus nucleocapsid assembly and function regulated by VP24 A critical transition appears to occur during assembly: the disordered tail of NP extends into an ordered helix, an event that links NP oligomerization, RNA packaging, and the recruitment of accessory proteins into a single coordinated process.20PubMed Central. Structure and assembly of the Ebola virus nucleocapsid
Mature nucleocapsids are ferried to the plasma membrane, where VP40 takes charge of the final exit. VP40 oligomerizes extensively at the inner leaflet of the membrane, and this process depends on specific lipids. The membrane lipid phosphatidylserine promotes the initial formation of VP40 hexamers from dimers, while a second lipid, PI(4,5)P2, stabilizes and extends those oligomers into the large lattice structures needed for budding.21PubMed Central. The Ebola Virus matrix protein, VP40, requires phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) for extensive oligomerization at the plasma membrane and viral egress Detailed analysis has shown that two distinct lysine-rich regions on VP40 handle these lipid interactions differently: one region preferentially binds PI(4,5)P2 and controls the extent of oligomerization, while the other stabilizes oligomers via lipid contacts and is more directly involved in particle release.22PubMed Central. PI(4,5)P2 binding sites in the Ebola virus matrix protein VP40 modulate assembly and budding
VP40 also recruits host machinery to pinch off the budding particle. It carries two short peptide motifs that interact with the host proteins Tsg101 and Nedd4, both of which normally participate in sorting cellular cargo into vesicles. Tsg101 binds a PT/SAP motif on VP40 regardless of its shape, while Nedd4 recognizes a PPXY motif only when VP40 is in its oligomeric, ring-like conformation.23PubMed. Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4 By co-opting these two independent cellular pathways, the virus essentially commands the host cell’s own membrane-sculpting equipment to wrap and seal new viral particles.
Shutting Down the Immune Response
Ebola’s lethality owes a great deal to its ability to suppress the interferon system, the body’s frontline antiviral defense. Two viral proteins share this job, and they attack the pathway at different points.
VP35 blocks the production of interferon in the first place. When a cell detects double-stranded RNA, a signature of viral replication, it normally activates signaling proteins that switch on interferon genes. VP35 binds double-stranded RNA and sequesters it, preventing detection. It also directly antagonizes PACT, a cellular protein that activates the RNA-sensing pathway, and experiments showed that VP35 expression shuts down virus-induced and PACT-induced interferon-beta production.24Cell Host & Microbe. Mutual Antagonism between the Ebola Virus VP35 Protein and the RIG-I Activator PACT Determines Infection Outcome Mutations in VP35’s RNA-binding region cripple its ability to suppress interferon and weaken the virus both in cell culture and in animals, underscoring how central this function is to virulence.25PubMed Central. Structure of the Ebola VP35 interferon inhibitory domain
VP24 attacks further downstream. Even if a cell manages to produce some interferon, the signaling molecule STAT1 must travel into the nucleus to turn on hundreds of antiviral genes. VP24 blocks this step by binding to karyopherin alpha1, the transport protein that normally escorts phosphorylated STAT1 through the nuclear pore. VP24 competes directly with STAT1 for the same binding site on karyopherin alpha1, and when VP24 wins that competition, STAT1 stays stranded in the cytoplasm.26PubMed Central. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation Structural work has mapped this interaction: VP24 binds karyopherin alpha at armadillo repeats 8 through 10, overlapping the site where STAT1 would normally dock.27Cell Host & Microbe. Structure of Ebola Virus VP24 Bound to Karyopherin Alpha Provides Insights into Inhibition of Host Interferon Signaling This means VP24 blocks both type I and type II interferon signaling in a single stroke, since both pathways depend on STAT1 nuclear import via the same transporter.28PubMed Central. The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin α1 and partially alters its nuclear import
What Happens in the Body
Ebola’s preferred first targets are dendritic cells and macrophages, immune cells that are supposed to sound the alarm. By infecting dendritic cells early, the virus disables the interferon system before adaptive immunity has a chance to organize. Infected macrophages then release a flood of inflammatory signaling molecules and tissue factor, a protein that triggers the clotting cascade.29PubMed. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever This creates a destructive combination: widespread inflammation, disseminated intravascular coagulation (the formation of small clots throughout the vasculature that paradoxically depletes clotting factors and leads to bleeding), and damage to blood vessel linings that causes fluid leakage.30PubMed. Clinical features and pathobiology of Ebolavirus infection
For years, it was assumed that the virus directly destroyed endothelial cells, the cells lining blood vessels, to cause hemorrhage. Primate studies challenged that assumption: viral replication in endothelial cells was not consistently seen until late in infection, well after clotting abnormalities had already begun, and endothelial cells remained relatively intact even at terminal stages. Even in cell culture, heavy viral replication produced surprisingly little cell death.31PubMed Central. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells Instead, the vascular damage appears to be mostly immune-mediated: virus-like particles carrying GP can activate endothelial cells and reduce their barrier function, and this effect is amplified by TNF-alpha, one of the inflammatory molecules released by infected macrophages.32PubMed Central. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function The hemorrhage, in other words, is largely a consequence of the immune system’s own overreaction rather than the virus physically tearing holes in blood vessels.
Antibody-Based Therapies and the Entry Pathway
The detailed understanding of how Ebola enters cells has directly informed the design of therapeutic antibodies. Two monoclonal antibodies, mAb100 and mAb114, illustrate how targeting different steps of the entry process can neutralize the virus. mAb100 binds the base of the GP trimer and physically blocks access to the loop that cathepsins must cut, preventing the proteolytic priming that is essential for infection. mAb114 takes a different approach: it binds the glycan cap and the inner chalice of GP, stays attached even after cathepsin processing removes the glycan cap, and blocks the trimmed GP from engaging NPC1.33PubMed Central. Structural and molecular basis for Ebola virus neutralization by protective human antibodies Other neutralizing antibodies have been characterized that appear to prevent the final fusion step rather than blocking receptor binding or cathepsin cleavage.34The Journal of Infectious Diseases. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP Collectively, these approaches show that GP’s multi-step entry process creates multiple vulnerable windows.
Viral Persistence in Survivors
Even after a person recovers from acute Ebola infection, the virus can linger in immune-privileged sites that are harder for antibodies and immune cells to reach. Research in monkeys treated with monoclonal antibodies revealed something striking: while the virus was cleared from every other organ, it persisted in the brain’s ventricular system, particularly in macrophages infiltrating the choroid plexus. Infection of the choroid plexus endothelium led to destruction of ependymal cells that form the blood-cerebrospinal fluid barrier, causing severe inflammation including ventriculitis, choroid plexitis, and meningoencephalitis. In some animals, this persistence led to fatal recrudescence of infection confined entirely to the brain.35PubMed. Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors These findings carry implications for human survivors treated with antibody therapies, suggesting that clearing the virus from the blood does not guarantee clearing it from the central nervous system. This is one reason why post-recovery monitoring remains important and why researchers are working on therapies capable of crossing the blood-brain barrier.
Working with Ebola in the Laboratory
Handling live Ebola virus requires Biosafety Level 4 (BSL-4) containment, the highest classification. Researchers work in pressurized suits with independent air supplies, and all materials are decontaminated before leaving the facility. Diagnostic testing during outbreaks presents its own challenges: specimen collection, transport, and processing all require rigorous biosafety protocols. Standard confirmation of infection relies on detecting the viral genome by reverse-transcription PCR, along with antigen-detection assays and antibody-based tests.36PubMed. Laboratory diagnosis of Ebola virus disease and corresponding biosafety considerations in the China Ebola Treatment Center Filovirus strains used in diagnostic kit development are grown in specialized cell lines under BSL-4 conditions.37The Journal of Infectious Diseases. Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories The practical consequence is that much of the foundational research on Ebola biology has been conducted using virus-like particles or pseudotyped viruses that can be handled at lower containment levels, which is why so many of the studies cited throughout this article reference VLPs rather than live Ebola. This workaround has been productive, but it means certain aspects of the virus’s behavior in real infection are harder to study and remain less well understood than the equivalent details for viruses that can be handled in ordinary labs.